The Health Minister officials claim that the approval of the Zydus Cadila’s ZyCoV-D COVID-19 vaccine will take few more days. Those aged 12 years or more will be eligible to take the vaccine.
The vaccine has shown positive results in all three phases (Phase 1, Phase 2 and phase 3) but is currently under examination.
A member of NITI Aayog, VK Paul, concluded that if everything went well, then the vaccine might be available in August-September.
The best part is the vaccine is not required to store at low temperatures. The sufficient temperature for the storage is 2-8 degrees Celsius.
The new study has claimed that the vaccine is efficient against new mutants especially, the Delta variant.
What is ZyCOV-D?
The three-dose DNA-plasmid ZyCOV-D vaccine will be administered intradermally through a needle-free injection. It means that the vaccine is genetically engineered, non-replicating a type of DNA, otherwise known as ‘plasmid.’
Here, the plasmids are coded with instructions to build a spike protein of COVID. The vaccination instructs the cells of the recipient to construct a spiky outer layer. It signals the immune system to recognize the threat and develop the antibody in response.
Unique Features of ZyCOV-D
Zydus Cadila COVID vaccine, otherwise known as ZYCOV-D, is the world’s first DNA based vaccine. If approved, it will be the fourth vaccine to get a green signal from Indian Health Ministry. The approval of ZyCOV-D will help to eliminate vaccine shortages in several states.
The vaccination has been tested on children aged 12 years to 18 years. The sources claim that there will be sufficient data to establish whether the vaccine should be approved for children.
As for now, the officials are hopeful that the vaccine may get a green signal from the ministry. Based on the positive results, there is a massive expectation that the vaccine will get approval in a few days.
Most COVID vaccines are given in two doses, whereas; the ZyCOV-D is jabbed in three shots. Also, the new age vaccine doesn’t require any needle to jab the recipient.
Here, the spring-powered delivers the shots of the ZyCOV-D vaccine. The narrow stream of fluid enters the skin of the recipient.
The Department of Biotechnology under the central government and the Indian Council of Medical Research (ICMR) has supported developing the vaccine.
Is the ZyCOV-D vaccine effective against the Delta variant?
The second wave of the pandemic has swayed all sections of the society while disrupting many lives and livelihoods. There have been some speculations on whether the approved vaccines are effectively against the new mutation, especially the Delta variant.
The medical representatives have recognized that the Delta variant is dangerous amongst all variants.
The trial of the third phase of the ZyCOV-D vaccine is conducted in 50 clinical sites during the second wave of the pandemic.
The Delta virus is the most concerned of all variants in the second wave. The authorities expect that the new vaccine will be effective against the new variant.
The chairman of the Zydus group Pankaj R Patel claimed that 99 per cent of all strains are Delta variants.
The peak of COVID was in April, May and June. He also claimed that the company might upgrade ZyCOV-D, if needed, to fight against the other variant.
Let us look into the list of vaccines available in India.
Currently, India has approved Covishield, Covaxin and Sputnik V. After the approval of Covishield and Covaxin, many states in India faced vaccine shortage, leading to massive deaths.
India faced backlashes from many International media houses, remarking the poor management in the health sectors.
With the approval of the third vaccine Sputnik V, India once again speeded up the inoculation drive to fight COVID.
Hyderabad- based Bharat Biotech International Limited, in collaboration with ICMR and National Institute of Virology, Pune, has developed Covaxin.
The vaccine consists of a dead virus incapable of infecting people but can instruct the immune system to establish a defensive reaction against an infection.
The vaccine is developed to carry the coronavirus pipe protein into human cells. The injected vaccine instructs the body on how to fight against similar viruses.
The efficacy of Covishield ranges between 70% to 90%, depending on the gap between the first dose and the second dose.
Sputnik V claims to report no stronger allergies. It uses two different vectors for the two shots during the vaccination that provides immunity for a longer duration.
The vaccine is considered to be well-proven and well-studied.
COVID virus has disrupted several lives. Now with numerous people being unemployed, the country is gearing up the inoculation drive.
Significantly, people need to remain wise and follow the COVID protocols while travelling.